Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.09 +0.99%
EPS Growth %: -60.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: -60.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.26 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Oddity Tech Ltd. (ODD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
